GRUENDELPARTNER advises WMS on its investment in ROTOP

The Saxony SME Growth Fund (WMS) is investing in ROTOP alongside healthcare specialists GENUI and SHS Capital.

ROTOP Pharmaka GmbH, founded in 2000 and based in Dresden-Rossendorf, is a leading supplier of radiopharmaceutical products. Radioactive medicines are being used with increasing frequency, both for diagnostic applications and for therapeutic purposes; in nuclear medicine, for example, for imaging or for targeted therapy in the treatment of certain types of cancer. The use of radiopharmaceutical products offers the advantage of highly targeted efficacy and largely avoids damage to healthy tissue.

GRUENDELPARTNER provided legal advice to WMS as part of this financing round.

GRUENDELPARTNER’s M&A, Venture Capital and Private Equity practice group is one of the most experienced and best-staffed advisory units in Central Germany and supports investors and entrepreneurs through all stages of development, particularly in company formation, business development, corporate finance and all exit processes.